IITRI is happy to share the promising news of one of our Sponsors, Ascletis Pharma, Inc.

Our team here at IITRI was contracted to perform in vitro testing of their drug candidates for antiviral effects against multiple strains of SARS-CoV-2 as well as cytotoxicity. ASC11, one of their oral small molecule drug candidates ( a 3-chymotrypsin like protease (3CLpro) inhibitor) showed potential as a COVID-19 antiviral against the wild type and variants. Together with other data presented on the candidate, these data show promise as the drug moves into further preclinical studies. A second candidate also shows similar antiviral potency and safety in Vero E6 cells as well.

“We are excited about our oral small molecule preclinical drug candidates for their potential to be best-in-class antiviral treatment of COVID-19,” said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, “These preclinical drug candidates demonstrate our discovery capability as a leading antiviral biotech.”

Here at IITRI, we look forward to continuing to work with Ascletis and other partners in the fight against COVID-19.

Read the full press release here.